Species diversity of non-tuberculous mycobacteria isolated from humans, livestock and wildlife in the Serengeti ecosystem, Tanzania. by Katale, Bugwesa Z et al.
MacFarlane, A; Mondragon-Gonzalez, R; Vega-Lopez, F; Wieles, B;
de Pena, J; Rodriguez, O; Suarez Y de la Torre, R; de Vries, RR;
Ottenhoff, TH; Dockrell, HM (2001) Presence of human T-cell re-
sponses to the Mycobacterium leprae 45-kilodalton antigen reflects
infection with or exposure to M. leprae. Clinical and diagnostic lab-
oratory immunology, 8 (3). pp. 604-11. ISSN 1071-412X
Downloaded from: http://researchonline.lshtm.ac.uk/16452/
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: Creative Commons Attribution Non-commercial No Derivatives
http://creativecommons.org/licenses/by-nc-nd/2.5/
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY,
1071-412X/01/$04.0010 DOI: 10.1128/CDLI.8.3.604–611.2001
May 2001, p. 604–611 Vol. 8, No. 3
Copyright © 2001, American Society for Microbiology. All Rights Reserved.
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The ability of the 45-kDa serine-rich Mycobacterium leprae antigen to stimulate peripheral blood mononu-
clear cell (PBMC) proliferation and gamma interferon (IFN-g) production was measured in leprosy patients,
household contacts, and healthy controls from areas of endemicity in Mexico. Almost all the tuberculoid
leprosy patients gave strong PBMC proliferation responses to the M. leprae 45-kDa antigen (92.8%; n 5 14).
Responses were lower in lepromatous leprosy patients (60.6%; n 5 34), but some responses to the 45-kDa
antigen were detected in patients unresponsive to M. leprae sonicate. The proportion of positive responses to
the M. leprae 45-kDa antigen was much higher in leprosy contacts (88%; n 5 17) than in controls from areas
of endemicity (10%; n 5 20). None of 15 patients with pulmonary tuberculosis gave a positive proliferation
response to the 45-kDa antigen. The 45-kDa antigen induced IFN-g secretion similar to that induced by the
native Mycobacterium tuberculosis 30/31-kDa antigen in tuberculoid leprosy patients and higher responses than
those induced by the other recombinant antigens (M. leprae 10- and 65-kDa antigens, thioredoxin, and
thioredoxin reductase); in patients with pulmonary tuberculosis it induced lower IFN-g secretion than the
other recombinant antigens. These results suggest that the M. leprae 45-kDa antigen is a potent T-cell antigen
which is M. leprae specific in these Mexican donors. This antigen may therefore have diagnostic potential as
a new skin test reagent or as an antigen in a simple whole-blood cytokine test.
Leprosy is a chronic infectious disease of the skin and pe-
ripheral nerves caused by infection with Mycobacterium leprae.
Leprosy patients present with a spectrum of clinical disease
that is closely correlated with the ability of the host to make a
cellular immune response to the organism (19). Tuberculoid
leprosy patients have strong cell-mediated immunity to M.
leprae both in vitro and in vivo, and few bacilli are present in
skin lesions. At the other end of the spectrum, T cells from
lepromatous leprosy patients are nonresponsive to M. leprae
and there is uncontrolled growth of the organism in skin le-
sions, often leading to disability and social isolation. The wide-
spread implementation of multidrug therapy during the past 10
years has resulted in a dramatic reduction in the numbers of
registered leprosy patients (25). Despite these achievements, it
is presently unclear whether the implementation of multidrug
therapy has had any effect on M. leprae transmission or reduced
the incidence of disease (34), as the number of new cases being
reported each year has remained the same at over 500,000
worldwide (25). Therefore, a major priority in leprosy research
is the identification of new specific M. leprae antigens for use as
skin test reagents to identify those who have been exposed to
the organism and also to help detect individuals with early
subclinical infection (21).
A number of antigens have been reported to induce T-cell
responses from tuberculoid leprosy patients and leprosy pa-
tient contacts in vitro, including the 70-, 65-, 18-, and 10-kDa
heat shock proteins (2, 6, 9, 15, 16, 22, 26), the 30/31-kDa
secretory proteins (13–15), and the M. leprae 35-kDa antigen
(28). However, all these M. leprae antigens have been shown to
be cross-reactive, with homologous genes identified in other
mycobacterial species (27, 36), and thus would not be useful as
diagnostic reagents.
The importance of gamma interferon (IFN-g) in reducing
infection with M. leprae is well documented in vitro and in vivo.
Th1 T cells specific for mycobacterial antigens have been iso-
lated from the lesions and peripheral blood of tuberculoid
leprosy patients (8, 17, 23). The skin lesions from tuberculoid
leprosy patients have also been shown to contain abundant Th1
cytokine mRNA, which was rare in lepromatous lesions (35).
Furthermore, when skin lesions of lepromatous leprosy pa-
tients were inoculated with recombinant IFN-g, marked reduc-
tions in bacterial load were observed (11). The ability to induce
secretion of IFN-g is therefore an important property of those
leprosy antigens involved in protective immunity.
Vega-Lopez et al. (29) used pooled sera from lepromatous
* Corresponding author. Mailing address: Immunology Unit, De-
partment of Infectious and Tropical Diseases, London School of Hy-
giene & Tropical Medicine, Keppel St., London WC1E 7HT, United
Kingdom. Phone: 44 20 7927 2466. Fax: 44 20 7637 4314. E-mail: Hazel
.Dockrell@lshtm.ac.uk.
† Present address: University College London Hospitals, Depart-
ment of Dermatology, London W1N 8AA, United Kingdom.
604
leprosy patients to screen an M. leprae lambda gt11 expression
library (37) and isolated and sequenced a gene encoding a
serine-rich protein with a predicted molecular mass of 45 kDa;
(25L or Sra) (27). A high proportion of leprosy patient sera
(78% of multibacillary and 68% of paucibacillary leprosy pa-
tient sera) contained immunoglobulin G (IgG) antibodies to a
b-galactosidase 45-kDa fusion protein (29). Work by others
(20) suggested that this antigen may be specific to M. leprae as
DNA from Mycobacterium tuberculosis and several atypical
mycobacteria failed to hybridize with a 45-kDa protein-encod-
ing DNA probe in Southern blots. We have now compared
peripheral blood mononuclear cell (PBMC) proliferation and
IFN-g production by leprosy patients in response to the 45-
kDa protein with those induced by other proteins including the
65-, 30/31-, and 10-kDa antigens, as well as the M. leprae
thioredoxin (Trx) and thioredoxin reductase (TR) proteins
(31–32). These responses were compared with those of leprosy
contacts, healthy individuals living in the same house as a
leprosy patient, patients with pulmonary tuberculosis, and in-
dividuals living in a leprosy-endemic area in order to evaluate
whether the 45-kDa antigen contains M. leprae-specific T-cell
epitopes.
MATERIALS AND METHODS
Patient population and controls. Leprosy patients were recruited from the
Centro Dermatologiico Dr Ladislao de la Pascua, Mexico City, Mexico, the
Hospital del Especialidades de Centro Medico Nacional Siglo XXI (IMSS),
Mexico City, Mexico, the Centro Medico La Raza, Mexico City, Mexico, and the
Hospital Amigo del Nino y la Mujer, Celaya, Mexico. Patients were categorized
according to clinical diagnosis, histopathology, and bacterial index of skin slit
smears. A total of 48 leprosy patients were used for the study. The tuberculoid
leprosy patient group consisted of 9 polar tuberculoid (TT) and 5 borderline
tuberculoid (BT) patients, and the lepromatous leprosy patient group was made
up of 34 individuals with the diffuse or nodular forms of lepromatous leprosy. All
the leprosy patients recruited were receiving chemotherapy at the time of the
study. The contact group consisted of 17 healthy individuals living in the same
house as a leprosy patient. Of these, 14 were contacts of lepromatous leprosy
patients, 2 were contacts of patients with the indeterminate form of disease, and
one was a contact of a borderline case. A further 20 healthy blood donors with
no known exposure to the disease were recruited from the Hospital Amigo del
Nino y la Mujer, in the leprosy-endemic area of Guanajuato, and Centro Der-
matologico Dr Ladislao de la Pascua. Eighteen patients with pulmonary tuber-
culosis were also recruited from the Instituto Nacional de Enfermedades Res-
piratorias, Mexico City, Mexico.
Antigens. Phytohemagglutinin (PHA-P) was supplied by Difco (Detroit,
Mich.) and used at a 1:200 dilution. Purified protein derivative (PPD) from M.
tuberculosis (batch RT48) was obtained from the Statens Serum Institute
(Copenhagen, Denmark). Armadillo-derived M. leprae sonicate (batch CD235)
(prepared as described in the report of the fifth meeting of the Scientific Working
Group on the Immunology of Leprosy, World Health Organization [WHO]
document TDR/IMM-LEP-SWG [5] 80.3, annex 4, p. 23, 1980) was kindly
provided by R. J. W. Rees (National Institute for Medical Research, Mill Hill,
United Kingdom). The 30/31-kDa antigen (1) was purified from the culture
filtrate of M. tuberculosis H37Rv as outlined previously (5). The M. leprae 65- and
10-kDa recombinant antigens used in the study were kindly provided by J. van
Embden and M. Singh through the WHO Immunology of Mycobacteria antigen
bank.
The M. leprae 45-kDa antigen was prepared by subcloning the 45-kDa-protein
gene (20) into the pTrcHisB vector (Invitrogen BV, Groningen, The Nether-
lands); the expressed protein was purified under denaturing conditions using a
nickel chelate affinity resin (Qiagen, Chatsworth, Calif.) (31), and the purified
protein fractions were dialyzed against phosphate-buffered saline (PBS). The
recombinant M. leprae Trx and TR, as well as a negative histidine control (His)
prepared from Escherichia coli containing the same pTrcHisB vector without an
insert, were prepared and purified as for the 45-kDa antigen, except that the
IPTG (isopropyl-b-D-thiogalactopyranoside) induction step was performed at
22°C rather than 37°C for the Trx and TR proteins. This was followed by
sonication under nondenaturing conditions to avoid the formation of insoluble
aggregates (31–32). The purity of the 45-kDa antigen was confirmed on Coo-
massie blue-stained sodium dodecyl sulfate–12% polyacrylamide gel electro-
phoresis gels, and visible contamination with E. coli proteins was excluded by
immunoblotting using a peroxidase-labeled rabbit anti-E. coli antiserum (Dako-
patts, Glostrup, Denmark). Single batches of each antigen were used throughout
the study. All the purified and recombinant mycobacterial antigens were used at
final concentrations of 10, 1, and 0.1 mg/ml; data shown are for the responses to
the antigens used at 10 mg/ml, which was shown to be optimal (results not
shown). The histidine tag control was used as a negative control for both the
histidine sequence and for any contaminating E. coli proteins. This control was
used at a final dilution of 1 in 100, comparable to that of the test antigen.
PBMC separation. Heparinized blood from healthy contacts, controls from
areas of endemicity, and patients was diluted with an equal volume of RPMI
1640 and then layered over Histopaque 1077 (Sigma Chemical Co., Poole,
Dorset, United Kingdom), followed by centrifugation at 400 3 g for 30 min. The
PBMCs were isolated from the plasma-Histopaque interface, washed three times
with Hanks’ balanced salt solution (Gibco BRL, Paisley, United Kingdom), and
suspended in growth medium consisting of RPMI 1640 (Gibco BRL) containing
10% autologous plasma, 100 U of penicillin/ml, 100 mg of streptomycin/ml, and
2 mM L-glutamine (Gibco BRL). PBMCs were counted using the trypan blue
exclusion method.
T-cell proliferation assays. T-cell proliferation assays were performed as pre-
viously described (6). Aliquots of 2 3 105 PBMCs in 180 ml of growth medium
were dispensed into each well of 96-well round-bottom microtiter plates (Gibco
BRL) containing either mitogen or antigen in triplicate wells. All the mycobac-
terial antigens were used at a final concentration of 10 mg/ml, which had previ-
ously been shown to be optimal. Negative-control cultures contained PBMCs in
growth medium alone. Plates were incubated for 6 days at 37°C in a humidified
atmosphere of 5% CO2 and 95% air and then were pulsed with 1 mCi of
methyl-[3H]thymidine (specific activity, 2 Ci/mmol; Amersham International,
Little Chalfont, United Kingdom). Cells were harvested 16 h later onto glass
fiber filter discs (Cambridge Technology, Cambridge, Mass.) using a semiauto-
matic cell harvester (PHD; Cambridge Technology). The discs were transferred
into biovials (Beckman, High Wycombe, United Kingdom), and 1.5 ml of scin-
tillation fluid (Cytoscint ES; ICN Biomedicals Ltd., Irvine, Calif.) was added.
Incorporation of [3H]thymidine was determined using a Beckman LS 880 scin-
tillation counter. Proliferative responses to the antigens were considered positive
when the stimulation index (SI; counts per minute in stimulated cultures divided
by counts per minute in unstimulated cultures) was greater than 3 and the
increase in counts per minute in stimulated cultures minus that in unstimulated
cultures was .2,500 cpm; this criterion was used to calculate the percent re-
sponders for each antigen.
Enzyme-linked immunosorbent assay (ELISA) for the detection of IFN-g.
Supernatants from antigen-stimulated PBMCs and controls were stored at
220°C before testing. Immulon IV microtiter plates (Dynatech, Billingshurst,
United Kingdom) were coated with 100 ml of monoclonal antibody to human
IFN-g (MD-1; Gibco BRL) at 2.5 mg/ml in 0.1 M carbonate buffer, pH 9.6, and
incubated overnight at 4°C. The contents of the wells were discarded, and then
the wells were blocked with 2.5% bovine serum albumin (BSA) in PBS, followed
by incubation in a humid box for 1 h at 37°C. After three washes with PBS-Tween
20 (0.05%), sample supernatants (100 ml) or the IFN-g reference standard
(GIF86–04; kindly provided by Hoffman la Roche, Basel, Switzerland) was
added and the plate was incubated for 2 h at 37°C; this was followed by a
further four washes with PBS-Tween 20. Rabbit polyclonal antibody to hu-
man IFN-g (100 ml/well; kindly provided by P. Kaye, London School of
Hygiene & Tropical Medicine), diluted in PBS-Tween 20 containing 5%
human AB serum and 0.25% BSA, was added in order to detect bound IFN-g,
and the plate was incubated for another hour at 37°C. The washing stage was
repeated as before, and 100 ml of peroxidase-labeled goat anti-rabbit IgG
(heavy plus light chains) (KPL; Dynatech, Billingshurst, United Kingdom)
was added to all wells. After an incubation of 30 min at 37°C, the plate was
washed and 100 ml of tetramethylbenzidine substrate (Kirkegaard & Perry
Laboratories, Gaithersburg, Md.) was added. After 15 min, the color devel-
opment was read at 490 nm on a Dynatech MR600 microplate reader. The
assay was sensitive down to a lower limit of 3 U/ml and had an upper limit of
detection of 400 U/ml. The quantity of IFN-g present in the supernatants was
determined from a standard curve.
Statistical analysis. A nonparametric test (Mann-Whitney U test) was used to
evaluate the statistical significance of the data.
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RESULTS
Lymphocyte proliferation responses induced by the M. lep-
rae 45-kDa antigen. The M. leprae 45-kDa antigen was ex-
pressed as a recombinant protein with a leader sequence of six
histidine residues followed by a 24-amino-acid linker at the N
terminus (31). It was therefore important to exclude the pos-
sibility that there was any human T-cell recognition of this
leader sequence. PBMCs from a group of 13 Mexican tuber-
culoid leprosy patients and 20 controls from an area of ende-
micity were stimulated with the M. leprae 45-kDa antigen or
the histidine control prepared as described above. The results
confirmed that whereas the M. leprae 45-kDa antigen induced
positive proliferative responses, the histidine control did not.
The inability of the leader sequence to induce positive prolif-
eration responses was also confirmed in a group of 11 United
Kingdom donors and in a group of 13 patients with pulmonary
tuberculosis (results not shown).
The PBMC proliferative responses of tuberculoid leprosy
and lepromatous leprosy patients were compared with those of
healthy household contacts and individuals from a leprosy-
endemic area in standard 7-day proliferation assays using a
panel of mycobacterial antigens including the 45-kDa antigen
(Fig. 1). All leprosy patients, household contacts, and controls
from areas of endemicity gave strong proliferative responses to
the mitogen PHA (data not shown). The majority of tubercu-
loid leprosy patients had positive proliferative responses to M.
leprae sonicate and to the 45-kDa antigen (Fig. 1a). When the
proportion of responders was calculated using a SI of .3 and
an increase in counts per minute of .2,500 cpm to define a
positive response, the tuberculoid leprosy patients showed
FIG. 1. Lymphocyte proliferation responses induced by a panel of mycobacterial antigens. PBMCs from tuberculoid leprosy patients (TT/BT;
n 5 14) (a), lepromatous leprosy patients (LL; n 5 34) (b), controls from areas of endemicity (n 5 20) (c), and leprosy contacts (n 5 17) (d) were
stimulated with a panel of mycobacterial antigens at a final concentration of 10 mg/ml for 6 days as described in Materials and Methods, and
proliferation was assessed by uptake of tritiated thymidine. The results are expressed as counts per minute; the median background counts per
minute in unstimulated cultures were 126 cpm for TT/BT leprosy patients, 285 cpm for LL leprosy patients, 166 cpm for controls, and 236 cpm
for leprosy contacts. The antigens used were PPD of M. tuberculosis, M. leprae sonicate (Mlson), recombinant M. leprae 45-kDa antigen (45K),
native M.tuberculosis 30/31-kDa antigen (30K), recombinant M. leprae 65-kDa antigen (65K), and recombinant M. leprae 10-kDa antigen (10K).
Lines, medians of the groups. Responses were taken as positive if the SI (counts per minute in cultures plus antigen divided by background counts
per minute in cultures without antigen) was $3 with an increase in counts per minute (counts per minute in cultures plus antigen 2 counts per
minute in cultures without antigen) of $2,500 cpm.
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92.8% positive responders to both M. leprae sonicate and the
M. leprae 45-kDa antigen. A lower proportion responded to the
65-kDa and 10-kDa antigens (29 and 15%, respectively). Tu-
berculoid leprosy patients made significantly higher prolifera-
tive responses than lepromatous leprosy patients after stimu-
lation with M. leprae sonicate, the M. leprae 45-kDa antigen,
and the M. tuberculosis 30/31-kDa antigen (P , 0.05) (Fig. 1b).
Both tuberculoid leprosy and lepromatous leprosy patients
made equally good responses to PPD and equally poor re-
sponses to the 65-kDa and 10-kDa antigens. Only 35% of the
lepromatous leprosy patients failed to make PBMC prolifera-
tive responses to M. leprae sonicate, and a proportion of these
made PBMC proliferative responses to the recombinant M.
leprae 45-kDa antigen (25%) and to the M. tuberculosis 30/31-
kDa antigen (36%).
Compared with controls from areas of endemicity, tubercu-
loid leprosy patients made significantly higher PBMC prolifer-
ative responses to PPD, to 45- and 30/31-kDa antigens (P ,
0.01 for all antigens), and to M. leprae sonicate (P , 0.05) (Fig.
1c). Both groups made similarly low proliferative responses to
both the 65- and 10-kDa antigens (P . 0.05). However, com-
pared with the household contact group, tuberculoid leprosy
patients made significantly higher responses only to M. leprae
sonicate (P , 0.05) and the 45-kDa antigen (P , 0.01). Al-
though the PBMC proliferative responses to PPD and to the
30/31-, 65-, and 10-kDa antigens by tuberculoid leprosy pa-
tients were generally higher than those for the contact group,
these differences were not statistically significant.
If the M. leprae 45-kDa antigen is an immunodominant lep-
rosy antigen, one would predict that household contacts of
leprosy patients might show stronger responses than controls
from areas of endemicity. All the controls responded to M.
leprae sonicate, compared with 55% of the leprosy patient
contacts (Fig. 1c and d). In response to the 45-kDa antigen,
however, 88% of household contacts made positive PBMC
proliferative responses compared with 10% of controls. The M.
tuberculosis 30/31-kDa antigen induced positive responses in
71% of controls and 55% of household contacts compared with
40 and 12%, respectively, who responded to the 65-kDa pro-
tein (P , 0.05). When the absolute counts-per-minute values
were compared, it was found that there was no significant
difference between the response to M. leprae sonicate or the
30/31-, 65-, and 10-kDa antigens shown by the contacts and
that shown by the controls, although the contact group gave
significantly higher PBMC proliferative responses to both PPD
and the 45-kDa antigen (P , 0.01). Therefore the 45-kDa
antigen was the only leprosy antigen which gave significantly
higher responses in the contact group than in the controls.
IFN-g production by PBMCs in response to leprosy anti-
gens. Supernatants were removed from PBMC cultures after 6
days and assayed for IFN-g by ELISA. There was no significant
difference in IFN-g production among any of the groups tested
in response to the mitogen PHA (P . 0.05) (data not shown).
The pattern of IFN-g production in response to the antigens
tested in all groups of patients and controls paralleled the
PBMC proliferative responses (Fig. 2). The tuberculoid lep-
rosy patient group produced significantly higher IFN-g than
lepromatous leprosy patients in response to PPD, M. leprae
sonicate, and the 45- and 30-kDa antigens (P , 0.05) (Fig. 2a
and b). Patients in the tuberculoid leprosy group produced
significantly higher quantities of IFN-g than the contact group
in response to PPD (P , 0.01), M. leprae sonicate (P , 0.02),
or the 45- (P , 0.01), 30- (P , 0.02), and 65-kDa (P , 0.01)
antigens. Interestingly, IFN-g production in response to the
45-kDa antigen by tuberculoid leprosy patients was higher than
those in response to M. leprae sonicate and the 65- and 10-kDa
antigens and comparable to that in response to the 30/31-kDa
antigen. Compared with that by tuberculoid leprosy patients,
IFN-g production by controls was significantly higher in re-
sponse to PPD (P , 0.01) and the 30- (P , 0.02) and 65-kDa
(P , 0.01) antigens but similar to that in response to M. leprae
sonicate (P . 0.05). IFN-g production by PBMC from lepro-
matous leprosy patients in response to antigen was similar to
that of the contact group for all antigens (P . 0.05) except for
the 65-kDa antigen, which induced higher IFN-g responses in
the lepromatous leprosy patient group (P , 0.05). Compared
with those from the lepromatous leprosy group, PBMCs from
controls gave higher IFN-g production in response to all the
antigens except the 45-kDa antigen (P , 0.05).
The control group produced significantly higher IFN-g in
response to M. leprae sonicate, PPD, and the 30- and 65-kDa
antigens than the contact group (P , 0.01) (Fig. 2c and d). In
contrast, IFN-g production by PBMC in response to the 45-
kDa antigen was found to be higher in the contact group than
in the controls, but this difference was not statistically signifi-
cant (P . 0.05).
T-cell proliferation responses to the M. leprae Trx and TR
antigens. PBMCs from the same groups were also stimulated
with two other novel M. leprae antigens, prepared as histidine
fusion proteins and purified using the same procedure as for
the 45-kDa antigen. Neither the Trx nor the TR antigen in-
duced any positive proliferation responses in PBMC from con-
trols from areas of endemicity (Table 1). The Trx antigen
induced positive responses in 46% of the leprosy contacts
(median, 2,715 cpm) and in 23% of the tuberculoid leprosy
patients (median, 1,633 cpm). The TR antigen induced a sim-
ilar pattern of responses, although the numbers of responders
were lower, with 27% responders in the contact group and
15% responders in the tuberculoid leprosy group. Both anti-
gens induced low responses in the lepromatous leprosy pa-
tients. Therefore although all three recombinant antigens
seemed to be potentially leprosy specific, the responses to the
M. leprae 45-kDa antigen were higher than those to the other
fusion proteins. These results also confirmed that the re-
sponses to the 45-kDa antigen were not directed to the histi-
dine leader sequence.
Lymphocyte proliferation and IFN-g responses to the 45-
kDa antigen in patients with pulmonary tuberculosis. The M.
leprae 45-kDa antigen therefore appeared to induce stronger
T-cell responses than the other recombinant leprosy antigens
tested and appeared to be more strongly recognized by T cells
from leprosy patients and contacts than controls. As a further
test of specificity, a group of patients with active tuberculosis
was also tested for responses to the M. leprae 45-kDa antigen.
All the patients with pulmonary tuberculosis responded to
PHA (data not shown) and PPD. In contrast, none of the
patients tested responded to the 45-kDa antigen and only a
small number responded to the other recombinant antigens
(Fig. 3a). The responses to M. leprae sonicate in the patients
with tuberculosis were lower than those in the control group.
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The PBMC proliferative responses to the other antigens tested
were generally low and not significantly different from those in
the control groups (P . 0.05 for all antigens).
All the pulmonary tuberculosis patients gave strong IFN-g re-
sponses to PPD and to the M. tuberculosis 30/31-kDa antigen (Fig.
3b). No significant difference in IFN-g production by PBMCs
between tuberculosis patients and controls in response to either
PHA or PPD were found (P . 0.05). The highest concentrations
of IFN-g were produced in response to PPD and to the 65- and
30/31-kDa antigens, although they were not significantly different
from those produced by the control group. As seen for the pro-
liferative responses, the M. leprae 45-kDa antigen induced lower
FIG. 2. IFN-g responses induced by a panel of mycobacterial antigens. PBMCs from tuberculoid leprosy patients (TT/BT; n 5 14) (a),
lepromatous leprosy patients (LL; n 5 34) (b), controls from areas of endemicity (n 5 20) (c), and leprosy contacts (n 5 17) (d) were stimulated
with a panel of mycobacterial antigens at a final concentration of 10 mg/ml for 6 days as described in Materials and Methods, and IFN-g was
measured in the day 6 supernatants by ELISA. The median background concentrations of IFN-g in unstimulated cultures were 3 U/ml for TT/BT
leprosy patients, 3 U/ml for LL leprosy patients, 6 U/ml for leprosy contacts, and 4 U/ml for controls. The antigens used were PPD of M.
tuberculosis, M. leprae sonicate (Mlson), recombinant M. leprae 45-kDa antigen (45K), native M. tuberculosis 30-kDa antigen (30K), recombinant
M. leprae 65-kDa antigen (65K), and recombinant M. leprae 10-kDa antigen (10K). Lines, medians of the groups.
TABLE 1. Lymphocyte proliferation responses induced by the M. leprae 45-kDa, Trx and TR antigensa
Antigen
Response (% responders) for:
TT/BT leprosy
patients (n 5 13)
LL leprosy
patients (n 5 11)
Contacts
(n 5 11)
Endemic controls
(n 5 20)
Pulmonary tuberculosis
patients (n 5 18)
No antigen 126 285 236 166 119
45 kDa 7,398 (92.3%) 3,689 (54.5%) 4,703 (90.9%) 1,030 (10%) 761 (0%)
Trx 1,633 (23.1%) 1,978 (9.1%) 2,715 (45.5%) 529 (0%) 395 (5.6%)
TR 1,326 (15.4%) 1,700 (0%) 1,870 (27.3%) 375 (0%) 375 (5.6%)
a PBMC from tuberculoid leprosy (TT/BT) or lepromatous leprosy (LL) patients, leprosy contacts, Mexican controls from regions of endemicity, and patients with
pulmonary tuberculosis were cultured with added antigen (no antigen), with Trx or TR antigens (His), with the M. leprae 45-kDa antigen, or with M. leprae Trx or TR
antigens. The results are expressed as median counts per minute as measured by thymidine incorporation as described in Materials and Methods.
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IFN-g responses in the PBMC cultures from patients with pul-
monary tuberculosis than any of the other mycobacterial antigens.
A comparison of the percent responders in the lymphocyte
proliferation assay to both M. leprae sonicate and the M. leprae
45-kDa antigen between tuberculosis patients and leprosy pa-
tients, contacts, and controls is shown in Fig. 4. This highlights
the difference in recognition of the 45-kDa antigen in subjects
known to be infected or exposed to M. leprae compared to the
patients infected with M. tuberculosis and suggests that the M.
leprae 45-kDa antigen is being recognized as an M. leprae-
specific antigen.
DISCUSSION
Multidrug therapy has been highly successful in the treat-
ment of leprosy. However, the identification of novel antigens
FIG. 3. Lymphocyte proliferation and IFN-g responses in patients with pulmonary tuberculosis. PBMCs from patients with pulmonary
tuberculosis (n 5 18) were stimulated with a panel of mycobacterial antigens at a final concentration of 10 mg/ml for 6 days as described in
Materials and Methods, and proliferation was assessed by uptake of tritiated thymidine (a), or IFN-g was measured in the day 6 supernatants by
ELISA (b). The median of the background counts in unstimulated cultures was 119 cpm; the median background concentration of IFN-g in
unstimulated cultures was 2 U/ml. The antigens used were PPD of M. tuberculosis, M. leprae sonicate (Mlson), recombinant M. leprae 45-kDa
antigen (45K), native M. tuberculosis 30-kDa antigen (30K), recombinant M. leprae 65-kDa antigen (65K), and recombinant M. leprae 10-kDa
antigen (10K). Lines, medians of the groups. For the lymphocyte proliferation assays, responses were taken as positive if the SI (counts per minute
in cultures plus antigen divided by background counts per minute in cultures without antigen) was $3 with an increase in counts per minute (counts
per minute in cultures plus antigen 2 counts per minute in cultures without antigen) of $2,500 cpm.
FIG. 4. Comparison of percent responders to M. leprae sonicate and M. leprae 45-kDa antigen in leprosy patients, leprosy contacts, controls
from areas of endemicity, and tuberculosis patients, as measured by lymphocyte proliferation. PBMCs were stimulated with 10 mg of M. leprae
sonicate (Mlson)/ml or M. leprae 45-kDa antigen, as described in Materials and Methods, and proliferation was assessed by uptake of tritiated
thymidine. A positive response (responder) was defined as that giving a SI (counts per minute in cultures plus antigen divided by background counts
per minute in cultures without antigen) of $3 and an increase in counts per minute (counts per minute in cultures plus antigen 2 counts per minute
in cultures without antigen) of $2,500 cpm. The group sizes were 14 for tuberculoid leprosy (TT/BT), 34 for lepromatous leprosy (LL), 17 for
leprosy contacts, 20 for controls, and 18 for pulmonary tuberculosis.
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which could be used as specific, diagnostic antigens for leprosy
is still of major importance. The aims of the present study were
to test T-cell reactivity to the 45-kDa antigen, previously de-
scribed as an M. leprae-specific protein (20, 29), and to evaluate
the potential of the 45-kDa protein to identify individuals
exposed to M. leprae or with subclinical infection. A specific
skin test reagent could be an important epidemiological tool in
monitoring M. leprae transmission and disease distribution.
The results demonstrate that the M. leprae 45-kDa protein is a
potent T-cell antigen and that it may have diagnostic potential.
Tuberculoid leprosy patients showed the greatest T-cell re-
sponses to the M. leprae 45-kDa antigen, and, as 13 of 14 of the
tuberculoid leprosy patients tested responded to the 45-kDa
antigen, it may contain one or more genetically permissive or
promiscuous T-cell epitopes. Some lepromatous leprosy pa-
tients also showed good T-cell responses to M. leprae and to
the M. leprae 45-kDa antigen. Although lepromatous leprosy
patients are generally anergic to M. leprae (10), they can show
T-cell responses to individual M. leprae antigens (18, 26). The
45-kDa antigen was similar to the secreted M. tuberculosis
Ag85 (30/31-kDa) proteins in its capacity to stimulate T-cell
responses in leprosy patients and contacts. Secreted proteins
often appear to be immunodominant in the T-cell response to
M. tuberculosis (3), and, in leprosy, the 30/31-kDa Ag85 antigen
has been shown to induce strong responses in leprosy contacts
(15). The high response rates to the 45-kDa antigen reported
here are higher than those reported in Ethiopia using the L1 or
L4 fragment of the 45-kDa antigen (20). Another study in
Indonesia (12) showed that the histidine-tagged M. leprae 45-
kDa fusion protein only induced positive responses in 3 to 8%
of the leprosy patients and contacts tested. Further work is
required to assess if the 45-kDa antigen gives stronger T-cell
responses in some ethnic groups than others.
T-cell responses to the M. leprae Trx and TR antigens were
also assessed using recombinant antigens expressed and puri-
fied in the same way as the 45-kDa antigen. M. leprae is unusual
in that these proteins are expressed as a single fusion protein
(33). Both of these antigens were recognized by a proportion of
leprosy patients and household contacts but not by controls,
indicating the presence of M. leprae-specific epitopes. Trx and
TR could therefore also have potential as diagnostic reagents,
although overall the responses induced were less strong than
those stimulated by the 45-kDa antigen.
An important aim of this study was to assess the potential of
the M. leprae 45-kDa antigen as a diagnostic reagent. PBMC
proliferative and cytokine responses of patients were com-
pared with those of household contacts of leprosy patients and
individuals living in a leprosy-endemic area. The leprosy con-
tact group, generally considered at increased risk of developing
leprosy (7), showed very high responses to the M. leprae 45-
kDa antigen. Follow-up studies would be required to deter-
mine whether those contacts making poor T-cell responses to
the 45-kDa antigen are at greater risk of developing leprosy, as
proposed for poor IFN-g responders to M. leprae sonicate (24).
Similarly high proportions of contacts have been reported to
respond to other leprosy antigens such as the 35-, 18-, and
10-kDa antigens (6, 15, 28) and the Mycobacterium bovis BCG
30/31-kDa antigen (15). The M. leprae 65-kDa antigen gave
lower responses, although the proportions of responders dif-
fered in other studies (2, 9, 15).
One of the functions of a skin test reagent is to differentiate
individuals exposed to M. leprae from those merely living in
areas of endemicity. Only 10% of controls responded to the
45-kDa antigen compared with the 100% that responded to M.
leprae sonicate and 55% that responded to the 30/31-kDa an-
tigen, both of which contain cross-reactive T-cell epitopes.
Southern hybridization with a DNA fragment of the 45-kDa
protein gene failed to identify a similar gene in M. tuberculosis
or eight other atypical mycobacteria (20), although several
hypothetical protein homologues in M. tuberculosis have now
been identified (e.g., Rv0442c and Rv2108 [4]).
In conclusion, the data presented here show that the 45-kDa
protein is a potent T-cell antigen capable of inducing PBMC
proliferation and IFN-g production in leprosy patients. The
45-kDa antigen was strongly recognized by T cells from leprosy
patients and contacts but gave weak or negative responses in
controls and patients with tuberculosis. This suggests that the
M. leprae 45-kDa antigen may be of use as a diagnostic reagent,
either in a skin test or a simple whole-blood IFN-g assay (30).
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